Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy ...Middle East

The U.S. FDA has granted Fast Track designation to Lu AH69593, an oral orexin 2 receptor agonist, for the treatment of patients with narcolepsy The orexin 2 receptor is critically located in the main biological pathway involved in wakefulness and sleep-wake regulation Lu AH69593 is...

Hence then, the article about lundbeck receives fda fast track designation for lu ah69593 an investigational orexin 2 receptor agonist for narcolepsy was published today ( Thursday 23/07/2026 - 10:40 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy )

Also on site :

• Rosalind Eleazar Is a Hollywood Actress Fighting to Rebuild Her Life in Chris Rock’s ‘Misty Green’ Trailer
• Glass falls from 17th floor of SF high rise
• Godinger’s ‘Elegant’ Scalloped Crystal Serving Bowl Trio Brings the Old Money Look to Your Table for Less